Chromen-2-one Derivatives for Anopheles arabiensis Larvicidal Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing malaria, particularly targeting the Anopheles arabiensis mosquito vector, face challenges due to insecticide resistance, necessitating the development of potent new biological active compounds to effectively eliminate the vector at the larval stage.
Innovation Solution
A series of 4-[(substituted 1H-benzimidazol-2-ylsulfanyl)methyl]-6-substituted-2H-chromen-2-ones derivatives are synthesized through a one-step chemical method, demonstrating high larvicidal activity against Anopheles arabiensis with mortality rates exceeding 70% after 24 and 48 hours, offering a potential larvicidal agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing insecticides are used for malaria vector control, then initial larvicidal activity is effective, but insecticide resistance develops over time reducing efficacy
Solution Approach 1:
The patent applies parameter changes by developing a series of compounds with varying substituent groups (R1 and R2) on the core chromen-2-one structure. This allows systematic modification of chemical parameters to optimize larvicidal activity while maintaining resistance management capabilities. The structured variation of molecular parameters enables identification of compounds that overcome resistance mechanisms.
Solution Approach 2:
The invention creates composite chemical structures by combining the coumarin core with diverse heterocyclic moieties (benzimidazole, benzoxazole, benzothiazole, thiadiazole). This composite approach generates molecules with enhanced and varied biological activities, providing multiple modes of action that can effectively manage insecticide resistance while maintaining high larvicidal efficacy.
2Reliability
If new biological active compounds are developed to overcome resistance, then larvicidal activity improves, but development time and complexity increase
Solution Approach 1:
The patent segments the molecular structure into distinct functional modules: a core coumarin scaffold (providing base biological activity) and interchangeable heterocyclic substituent groups (providing enhanced activity and resistance management). This segmentation allows systematic development of potent compounds while maintaining a manageable structural framework that simplifies synthesis and characterization.
Solution Approach 2:
The invention creates a universal platform where a single core structure (coumarin with positions 4 and 6 substituted) can accommodate multiple different heterocyclic groups. This multi-functional approach allows one core compound to serve multiple purposes by simply changing the substituent, reducing overall development complexity while maintaining high larvicidal activity across different resistance scenarios.
3Reliability
If complex multi-step synthesis methods are used to create potent larvicides, then biological activity increases, but manufacturing cost and time increase
Solution Approach 1:
The patent merges multiple synthesis steps into a single efficient reaction pathway. The one-pot synthesis combines the formation of the coumarin core and attachment of heterocyclic substituents in one operational step, eliminating intermediate isolation and purification processes. This merging maintains high biological activity while dramatically improving synthesis efficiency and reducing manufacturing complexity.
Solution Approach 2:
The invention employs preliminary action by pre-synthesizing the core coumarin structure with reactive functional groups positioned for direct substitution. This preliminary preparation allows the final heterocyclic groups to be attached in a single step without requiring complex multi-stage synthesis, thereby maintaining potent biological activity while streamlining the manufacturing process.
Data Source
AI summary
Compounds for treating preventing malaria and, particularly, to larvicidal agents that are 4-[(substituted 1H-benzimidazol-2-ylsulfanyl)methyl]-6-substituted-2H-chromen-2-ones derivatives and their use as larvicidal agents.